placebo + pemetrexed

This is a combination regimen used in clinical trials, consisting of pemetrexed (a folate antimetabolite chemotherapy agent) and placebo. Pemetrexed inhibits several key enzymes involved in folate metabolism and DNA synthesis, thereby blocking the proliferation of rapidly dividing cancer cells. The "placebo + pemetrexed" arm is typically used as a control group in randomized studies to compare outcomes against active investigational treatments (such as immunotherapy plus chemotherapy). This combination does not represent an approved therapeutic product but rather a trial comparator arm, most notably seen in phase 3 studies for non-squamous non-small cell lung cancer (NSCLC), where patients receive standard-of-care pemetrexed with platinum-based chemotherapy and maintenance pemetrexed, with or without an additional investigational drug[6][10].